Stable overexpression of miR-17 enhances recombinant protein production of CHO cells  by Jadhav, Vaibhav et al.
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miRNAs  negatively  regulate  gene  expression  at post-transcriptional  level,  and  consequently  play  an
important  role  in  the control  of many cellular  pathways.  The  use of miRNAs  to  engineer  Chinese  hamster
ovary  (CHO)  cells  is an  emerging  strategy  to improve  recombinant  protein  production.  Here,  we  describe
the effect  of  transient  and  stable  miRNA  overexpression  on  CHO  cell  phenotype.  Using  an established  tran-
sient miRNA  screening  protocol,  the  effects  of miR-17,  miR-92a  and  cluster  miR17-92a  on CHO  growth
and  protein  productivity  were  studied  and  followed  by  analysis  of  cell  pools  with  stable  overexpressioneywords:
hinese hamster ovary (CHO) cells
icroRNA (miRNA)
iR-17
iR-92a;
iR17-92a cluster
roductivity
of  these  miRNAs.  CHO  cells  stably  engineered  with miR-17  exhibited  both  enhanced  growth  performance
and  a 2-fold  increase  in speciﬁc  productivity,  which  resulted  in  a  3-fold  overall  increase  in  EpoFc  titer.
While  further  studies  of miRNA–mRNA  interactions  will  be necessary  to  understand  the  molecular  basis
of this  effect,  these  data  provide  valuable  evidence  for  miR-17  as a  cell  engineering  target  to  enhance
CHO  cell  productivity.
© 2014  The  Authors.  Published  by Elsevier  B.V. Open access under CC BY license. . Introduction
Recombinant production of therapeutic proteins has surpassed
he 100 billion $ per year market volume and plays an important
ole in the global economy as well as in advanced medical care
Aggarwal, 2012; Brower, 2005). Today, a signiﬁcant fraction of
herapeutic proteins is produced in Chinese hamster ovary (CHO)
ells due to their regulatory approval, biosafety compliance and
bility to produce proteins with human-like glycosylation patterns.
HO cells inherently have high somatic genetic instability, which
enerates large clonal variation, a property that is commonly har-
essed for screening, selection and development of production
lones for expression of recombinant proteins (Hacker et al., 2009;
ayapal et al., 2007).
So far, several successful genetic engineering approaches have
een used to enhance CHO cell performance in relation to
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168-1656      © 2014 The Authors. Published by Elsevier B.V. 
ttp://dx.doi.org/10.1016/j.jbiotec.2014.01.032
Open access under CC BY license. apoptosis or autophagy, cell cycle (growth and proliferation), pro-
tein secretion and production, unfolded protein response (UPR)
and metabolic engineering (Arden and Betenbaugh, 2006; Baker
et al., 2001; Lee et al., 2013; Peng and Fussenegger, 2009; Wang
et al., 2012; Wlaschin and Hu, 2007). In addition to engineering the
expression of protein-coding genes, miRNAs have recently emerged
as a tool to modify the phenotype of CHO cells (Barron et al.,
2011b). RNAs are small non-coding RNA molecules, which nega-
tively regulate gene expression at the post-transcriptional level.
Similar to protein coding genes, transcription of most microRNAs
is controlled by RNA polymerase II promoters. The longer pri-
mary transcripts undergo cleavage in the nucleus to form a hairpin
like structure termed precursor microRNA (pre-miRNA) of 50–70
nucleotides length. Further, the pre-miRNA is exported from the
nucleus to the cytoplasm where it is incorporated into a multi-
meric protein complex consisting of Dicer, Ago1–4 and others, and
cleaved again to give rise to the miRNA induced silencing complex
(miRISC) encompassing a 17–22 nt long mature miRNA. Subse-
quent sequence speciﬁc targeting of the miRISC toward the 3′-UTR
of a target mRNA results either in the inhibition of mRNA trans-
lation or mRNA cleavage (Graves and Zeng, 2012; Havens et al.,
2012). In recent years miRNA research has enhanced our under-
standing of gene expression control and lead to a better view of
cellular physiology in both the normal as well as in a pathological
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tate of a cell (Cui et al., 2006; Grillari et al., 2010; Ha, 2011). Evi-
ence is accumulating for the great importance of small non-coding
NAs like piRNAs (Gerstl et al., 2013) and miRNAs in CHO cells for
any fundamental biological processes including cell division and
etabolism (Hatziapostolou et al., 2013), thus drawing the inter-
st of cell engineers to this class of RNA molecules (Barron et al.,
011b; Hackl et al., 2012a; Jadhav et al., 2013; Muller et al., 2008).
To date, around 350 CHO miRNAs were sequenced (Hackl et al.,
011) and annotated (Hackl et al., 2012b). In view of the biotech-
ological use of miRNAs, the correlation of miRNA transcription
o distinctive cellular phenotypes such as fast proliferation (Bort
t al., 2012; Clarke et al., 2012) or stress response (Druz et al., 2012)
as shown. In a recent study, the general importance of miRNA
xpression and the miRNA processing machinery in CHO cells was
escribed (Hackl et al., 2014). These studies provide the basis for the
evelopment of CHO cell lines with improved phenotypes through
ngineered miRNA expression.
We  have previously established a method for screening the
ffect of miRNA overexpression on growth and productivity of a
ecombinant EpoFc producing (EpoFc-CHO) model cell line (Jadhav
t al., 2012) and observed a positive effect of transient miR-17 over-
xpression on CHO cell growth without negatively affecting cell
peciﬁc productivity. A question remaining open with transient
verexpression was whether such short term effects of increased
iRNA expression remain valid in a cell line that continuously
nd stably overexpresses a miRNA. Here we therefore tested how
he transient effects of the entire miR-17–92a cluster, miR-17, or
iR-92a alone are consistent in stable overexpressing cell lines
nd how these growth enhancing miRNAs differ in their effects
hen overexpressed in recombinant EpoFc-CHO cell pools. Sta-
le miR-17 overexpression conﬁrmed a minor increase in growth
ate, while at the same time resulted in 3-fold increase in EpoFc
iters compared to controls. Overexpression of the entire miR-
7–92a cluster resulted in no change in growth rate, but a reduced
roductivity, while miR-92a overexpression reduced growth and
ncreased productivity. These results conﬁrm that while transient
ver-expression is well able to identify engimiRs for stable miRNA
ngineering of CHO cells, it is still necessary to generate stable over-
xpressing cell lines for a detailed analysis of their effects. Our
esults also show that miR-17 is one of the so far few miRNAs
emonstrated to boost productivity.
. Materials and methods
.1. Cell line and media
The recombinant CHO-EpoFc cell line was established as previ-
usly described (Lattenmayer et al., 2007) and was later adapted to
rowth in serum-free and l-glutamine free CD CHO medium (Gibco,
nvitrogen, Carlsbad, CA, USA) supplemented with 0.096 M MTX
nd 1 ml  anti clumping agent (Gibco, Invitrogen, Carlsbad, CA, USA)
er 500 ml  medium (Taschwer et al., 2012). Cell cultures were cul-
ivated in conical ﬂasks with a working volume of 30 ml  at 37 ◦C in a
umidiﬁed atmosphere containing 7% carbon dioxide and constant
haking at 140 rpm.
.2. Cloning miRNA expression plasmids
miRNA expression plasmids for miR-17 and miR-92a were
eveloped as previously explained (Jadhav et al., 2012) by
sing sequences from miRbase: miR17 = MI0020419, miR-
2a = MI0020560 (Kozomara and Grifﬁths-Jones, 2011). Brieﬂy,
himeric CHO pre-miRNAs were cloned into pcDNATM6.2-
W/±EmGFP-miR vector (Invitrogen Inc., USA) in the 3′
ntranslated (3′ UTR) region of the emerald green ﬂuorescenthnology 175 (2014) 38–44 39
protein (EmGFP) following the instruction manual. The miR17-92a
cluster was cloned by PCR amplifying the Human genomic region
(chr13: 92002682 + 92003780) containing the hsa-miR-17–92a
cluster using primers FP: GGATCCCTAAATGGACCTCATATCTTTGAG
and RP: GAATTCGAAAACAAGACAAGATGTATTTACAC and cloned
into BamHI and EcoRI sites of pcDNATM6.2-GW/±EmGFP-miR
vector. Sequences of all clones were conﬁrmed using standard
sequencing method.
2.3. Transient screening and generation of stable pools
The transient screening for candidate miRNA expression plas-
mids was carried out by standard protocol as previously described
(Jadhav et al., 2012). Brieﬂy, 1 × 107 cells in exponential growth
phase were transfected with 10 g of pcDNA6.2-EmGFP-miR plas-
mid  or pcDNA6.2-EmGFP-negative endo-free plasmid using the
Nucleofector II (Lonza, Basel, Switzerland) and Nucleofector Kit
V/program H-14. Post-transfection cells were seeded into 60 ml  of
pre-warmed culture medium in a conical ﬂask. Cells were allowed
to recover from electroporation in a static incubator at 37 ◦C for
2–3 h and then transferred to a humidiﬁed CO2 incubator with con-
stant shaking at 140 rpm. Data for growth and productivity were
recorded for the next four days.
For generation of pools with stable miRNA overexpression, cells
were transferred 24 h post-transfection to 96-well culture plates
containing 10,000 cells/well in selection media with 10 g/ml
Blasticidin-S (InvivoGen, California, USA). Cells were maintained
by adding 50% fresh medium every 3–4 days for 4 weeks. Sub-
sequently, surviving clones were expanded to 12-well plates for
another 4 weeks with selection pressure and ﬁnal pools were
picked based on the GFP expression proﬁles. Most of the selected
pools represented heterogeneous populations according to GFP
expression. Thus, secondary selection was done without antibiotics
selection pressure, but by sorting cells for homogenous GFP posi-
tive populations, followed by the generation of master cell banks
that were used for further characterization and analysis.
2.4. Cell sorting and ﬂow cytometry analysis
Cell sorting was  done for viable and GFP positive cells in bulk
using a FACS VantageTM (Becton Dickinson, Franklin Lakes, NJ,
USA), equipped with a Sort enhancement module. A combination
of a SSC-H/FSC-H gates and GFP positive sorting gates was  set
using non-transfected cells. GFP positive cells were detected with a
488 nm argon ion laser and ﬂuorescence was  measured using a BP
ﬁlter at 530/30 nm.  Sorted cells (100,000) were collected in a 6-well
plate with 3 ml  pre-warmed culture medium supplemented with
penicillin–streptomycin 1× concentration. After sorting, an aliquot
of the sorted cells was  run on the BD FACSCANTO to check the purity
of the populations twice weekly for all pools for two weeks. Another
round of sorting was done based on GFP expression once weekly
for two  weeks. Final pools deposited were homogenous and sta-
ble for GFP expression under normal culture conditions. All GFP
measurements were performed using a BD FACS CANTO (Becton
Dickinson, Franklin Lakes, NJ, USA) ﬂow cytometer. A minimum of
10,000 events were analyzed at excitation wavelength of 488 nm
using a 530/30 BP ﬁlter for collection of the emitted signal. Untrans-
fected cells were used as negative control for gating of GFP-positive
cells. Data were analyzed using the BD FACS DIVA software.
2.5. RNA isolation and quantitative real-time PCR1–5 × 106 cells were harvested and homogenized by vor-
texing in 1 ml  Trizol reagent (Invitrogen, Carlsbad CA, USA)
followed by 5-min incubation at room temperature and stored at
−80 ◦C until used. Total RNA was  isolated using the chloroform
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Fig. 1. Effect of transient overexpression of miRNAs on growth rate and recombinant protein titers: (A) effect of miRNA overexpression on the growth rate is represented
by  the average growth rate () calculated until day 4 of transient miRNA over-expression relative to the negative control transfection (NC). (B) Similarly, the effect on
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xperiments with two technical replicates each. *P < 0.05 to NC.
rotocol provided by the manufacturer. In the ﬁnal step RNA pel-
ets were resuspended in 30 l of nuclease free H2O. Absorbance
t 230, 260 and 280 nm was measured using the ND-1000 spec-
rophotometer (NanoDrop Technologies, DE, USA) to calculate RNA
uality and quantities. miRNA expression was measured using
 TaqMan miRNA quantitative PCR assay from Applied Biosys-
ems (Foster City, CA) that has been previously described (Cheng
t al., 2005). Brieﬂy, cDNA was made with 10 ng total RNA in
0 l reactions using MultiScribe reverse transcriptase (Applied
iosystems, Foster City, CA, USA) and speciﬁc TaqMan® primers
or each miRNA (TaqMan® miRNA Assay ID’s, MIR92a: ID-00431,
IR17: ID-002308, MIR185: ID-002271). The cycle parameters for
he RT reaction are 16 ◦C for 30 min, 42 ◦C for 30 min, 85 ◦C for
 min, and hold at 4 ◦C. The PCR mix  consists of the RT prod-
ct, TaqMan® 2× Universal PCR Master Mix  and the appropriate
× MicroRNA Assay Mix. The PCRs were run on the Corbett
otorgene rotorcycler (Qiagen, Germany) including 4 technical
eplicates per sample. The expression of each miRNA relative to
iR-185 (endogenous control) was determined using the Ct
ethod. Average fold differences were calculated by normaliz-
ng the relative expression (Ct values) to that in the negative
ontrol transfection. Average fold differences between batches are
resented.
.6. Analysis of growth and productivity
After selection of stable miRNA overexpressing pools their
erformance in batch culture was tested in small scale conical
asks. These batches were run in duplicate and repeated twice.
xponentially growing CHO-EpoFc cells were seeded in 60 ml  of
re-warmed culture medium at a density of 2 × 105 cells/ml. The
aily measurements of cell viability and viable cell density were
erformed using a ViCell analyzer (Beckman Coulter, USA) based
n the trypan-blue dye exclusion method. Total cell counts were
nalyzed using a Coulter Counter (Beckman Coulter, Fullerton, CA,
SA) after isolation of nuclei in 0.1 M citric acid (2% Triton X-100)
or at least 30 min. Growth data were further analyzed to calculate
peciﬁc growth rates using the formula  = (ln X2 − ln X1)/(t2 − t1)
here X1 and X2 is viable cell number at the respective time points
t1 and t2). The EpoFc concentration was quantiﬁed by ELISA as
escribed previously (Jadhav et al., 2012) using an ELISA reader
Sunrise, TECAN) at 492 nm and 620 nm as reference wavelengthon. The data are presented as mean (±standard deviation; SD) of three independent
and the software Magellan according to the instruction manual.
Speciﬁc productivity was calculated as qP = (Cp,n − Cp,1)/CD where
Cp is recombinant protein concentration at time n and CD is cumula-
tive cell density, which is calculated as CD =
∑
(Xi−1 − Xi)/, where
Xi is integral viable cell density and  is growth rate.
2.7. EpoFc gene copy number determination using real-time
Q-PCR
Gene copy number determinations were made by quantitative
PCR (Q-PCR). EpoFc PCR was  performed with speciﬁc primers and
as reference Bcl-2 was used, to develop a standard curve with
data points ranging from 103 to 108 copies. Primers used for PCR
were Bcl-2 FP: TTCAGCTCAAACTGGGCTTT, Bcl-2 RP: AACTTGAGCG-
GCTCCCTAAT, EpoFc FP: CATGGGGGTGCACGAATGTC, EpoFc RP:
CAAGCTGCAGTGTTCAGCAC. The Q-PCR runs were done using the
Corbett Rotorgene rotorcycler (Qiagen, Germany) system, ampliﬁ-
cation reactions (20 l) were performed in 4 technical replicates
per sample with 20 ng of input genomic DNA, 1 l of each primer
and 2 l of 5× SensiMixPlus SYBR master mix. PCR parameters were
as follows: an initial 10 min-denaturation step at 95 ◦C followed
by 40 cycles of 15 s at 95 ◦C, 10 s at 65 ◦C and 15 s at 72 ◦C. Speci-
ﬁcity of the primers was  veriﬁed by a melting curve analysis of the
PCR products with a temperature gradient of 0.2 ◦C/s from 68 ◦C to
98 ◦C. Copy number variation of EpoFc was determined as a ratio
of the estimated copies of EpoFc gene to that of the reference gene,
Bcl2.
3. Results
3.1. Effects of miRNA overexpression during transient transfection
Previously, we  proposed a screening platform for plasmid based,
transient miRNA overexpression to test for biological effects that
might change bio-industrially important cellular characteristics.
Thereby we  identiﬁed miR-17 as a promising engineering target
as its transient overexpression increased cell proliferation (Jadhav
et al., 2012). We  extended our experiment by testing whether the
whole miR-17–92 cluster, or the single miR  miR-92 might have
similar effects (Fig. 1). While miR-17 led to a 23 (±5)% and miR-
17–92 cluster to a 27 (±12)% increase of mean growth rate () over
the period of 4 days, miR-92a did not show signiﬁcant differences
V. Jadhav et al. / Journal of Biotechnology 175 (2014) 38–44 41
Fig. 2. Selection and characterization of stable miRNA expression clones: miRNA overexpression was  driven by a constitutive CMV  promoter with co-expression of GFP. (A)
The  panel shows GFP-expression (Fl-1H) of 4 stable-pools overexpressing the miR-17–92 cluster (SCM-1792), miR-17 (SCM-17), miR-92a (SCM-92a) and the no-miR-vector
control  (NC) after the entire selection process. All graphs are overlaid with ﬂuorescence of untransfected cells. (B) qPCR was performed to assess the miRNA overexpression.
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she  expression of miR-17 and miR-92a relative to miR-185 expression (endogenous c
y  normalizing the relative expression (Ct values) to that of the negative control t
n  when compared to the negative control (NC). Furthermore,
iR-17 showed a moderate (13 ± 4.7%), but signiﬁcant difference
n the EpoFc titer. These results encouraged us to test the inﬂuence
f these miRNAs in stable overexpression systems.
.2. Generation and characterization of stable miRNA
verexpressing pools
The advantage of vector-based systems for functional miRNA
creening is that the same vectors can immediately be used tol) was  determined using the Ct method. Average fold differences were calculated
ction.
generate stable miRNA overexpressing CHO  cells. Using the mam-
malian selection marker gene present on the vector, stable miR-17,
miR-92a and miR-17–92a cluster expressing pools were generated.
Such pools were preferred to clonal populations in order to reduce
the bias by the inherent clonal phenotypic variation observed in
CHO cells (Pilbrough et al., 2009). Generation of stable pools was
carried out in two-steps: ﬁrst we  performed antibiotic-selection
with Blasticidin-S (10 g/ml), followed by sorting for GFP positive
cells using FACS to enrich the miRNA expressing population. GFP
expressions of the ﬁnal selected populations are shown in Fig. 2A.
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Fig. 3. Analysis of culture performance of stable miRNA overexpressing EpoFc producers in shaken batch cultures: (A) mean viable cell density (primary y-axis) and viability
(secondary y-axis) of three independent batches of SCM-1792(), SCM-17(), SCM-92 (), and NC (©). (B) Integral of viable cell density (IVCD) reached until day 7. (C) EpoFc
(mg/L)  concentrations during the batch, quantiﬁed by ELISA. (D) Average speciﬁc productivity (qP) calculated from day 1 to day 7 of the batch. The data are represented as
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CM-17 (SCM = stable cells expressing miRNA), SCM-92a and neg-
tive control cells (NC) exhibited >90% GFP positive cells, while for
he miR-17–92a cluster (SCM-1792) we could only achieve 60% GFP
nrichment even after two rounds of GFP cell sorting. Since GFP
egative populations reappeared soon after each round of sorting,
e speculate that GFP negative cells are a consequence of destabi-
ized GFP translation due to the simultaneous cleavage of multiple
iRNAs from the 3′ UTR of GFP. To assess the miRNA overexpress-
on in these populations, total RNA was isolated from 106 cells and
iR-17, miR-92a and miR-185 (as reference gene) were analyzed
sing TaqMan real time qPCR assays. The fold changes relative to
iR-185 were determined using the Ct method and compared
o the NC population (Fig. 2B). For SCM-1792 cells the miR-17
nd miR-92a levels were found to be 3.5- and 2.0-fold increase.
n case of SCM-17 cells, miR-17 was 3.2-fold overexpressed, and as
xpected no signiﬁcant overexpression was observed for miR-92a.
ice-versa, SCM-92a exhibited only miR-92a upregulation. Thus,
he GFP and miRNA expression provided proof for successful stable
verexpression of speciﬁc miRNAs in these populations.
.3. The effects of stable miRNA overexpression on cell
roliferation and recombinant protein production
Stably engineered cells were cultivated in batch cultures in
haker ﬂasks to evaluate growth, viability and recombinant EpoFcplicates each. *P < 0.05 to NC.
production (Fig. 3). We  observed that both SCM-1792 and SCM-17
showed a minor increase in growth rate during early exponential
phase when compared to the NC population as indicated by spe-
ciﬁc growth rate analysis (data not shown). While SCM-17 cells
sustained this faster growth until the end of the batch and there-
fore showed a signiﬁcant increase in cumulative cell density of 15%
(Fig. 3B), SCM-1792 cells entered stationary phase earlier than the
control and therefore only reached a comparable cumulative cell
density relative to NC. SCM-92a cells, on the other hand, had both
a reduced growth and cumulative cell density.
The EpoFc protein titers in mg/L were observed to be signiﬁ-
cantly higher for SCM-17 cells (98.3 ± 25.3), compared to SCM-1792
(22.2 ± 3.4), SCM-92 (43.5 ± 12.8) and NC (31.8 ± 11.2) (Fig. 3C).
While SCM-1792 cells exhibited even weaker titers and speciﬁc
productivity compared to the negative control, SCM-92a cells
produced equal amounts of EpoFc. Surprisingly, miR-17 overex-
pression in SCM-17 cells resulted in a 3-fold increase in titer
compared to NC cells and a 2-fold increase in speciﬁc productivity
(qP, Fig. 3D). Therefore, it seems that miR-17 overexpression not
only increases cell proliferation but also modulates recombinant
protein production in these cells.To conﬁrm that this increase in protein production is due to miR-
17 overexpression and not due to other confounding factors such
as selection of a variant population, we  checked EpoFc gene copy
numbers by real-time qPCR (Fig. 4). The results show no signiﬁcant
V. Jadhav et al. / Journal of Biotec
Fig. 4. EpoFc gene copy number analysis: EpoFc gene copy numbers in the miRNA
overexpressing pools were analyzed using real-time Q-PCR. Shown is the relative
copy  number of EpoFc relative to the reference gene, normalized to the negative
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hanges in EpoFc gene copy numbers across all four pools, thus
onﬁrming the positive effect of miR-17 overexpression on growth
nd especially recombinant protein production in CHO cells.
. Discussion
In the past decade miRNA research has gained much attention in
iology and found broad applications including diagnostics, thera-
eutics and cell engineering (Barron et al., 2011b; Bratkovic et al.,
012; Hackl et al., 2012a; Jadhav et al., 2013; Osman, 2012). Here
e present results from both transient and stable overexpression
f mi-17, miR-92a and the entire miR-17–92 cluster on cell pro-
iferation and recombinant protein production in CHO cells. While
ransient screening is a fast approach to screen for promising can-
idates, one could argue that the effect of miRNA overexpression
or a period of 3–5 days may  be different from the effect generated
y a continuous, long term increase in their transcription. Thus, the
ransient screening approach requires stable engineering of cells
or validation of results and to ensure beneﬁcial effects for indus-
rial production of recombinant proteins. Our results show that the
ransient positive effects on growth could also be observed for the
tably engineered CHO cell pools during early exponential culture,
hich is indeed the state that is best reﬂected by the transient
rotocol. During later culture phases, however, the effects became
ore divergent: while both miR92a and the cluster signiﬁcantly
educed growth, resulting in a decreased (miR-92a) or comparable
miR-17–92a) IVCD relative to the control, miR-17 overexpress-
ng cells continued to grow, resulting in an increased overall IVCD.
 possible explanation for these diverging results is the fact that
RNA levels in cells during a batch culture are subject to continu-
us changes, as is the culture environment (Bort et al., 2012). Thus,
onstitutive miRNA overexpression could result in the repression of
ew targets as cell behavior changes during batch-cultivation and
esulting in a “new” effect different to that observed during the
hort transient testing phase. Nevertheless, initial transient testing
f miRNA effects enables time-efﬁcient pre-selection of promising
andidates, speciﬁcally if growth rate is a major target for engi-
eering as the set-up of the transient screening best mirrors early
xponential growth phase. In case other culture phases are of inter-
st (for instance increasing productivity during stationary phase)hnology 175 (2014) 38–44 43
the protocol for transient screening would have to be adapted
accordingly.
Unexpectedly, stable overexpression of miR-17 not only
enhanced growth, but also speciﬁc protein productivity (2-fold),
resulting in a 3-fold increase in titer. This is quite remarkable
in the context of cell engineering, since commonly growth and
speciﬁc productivity are inversely correlated to a certain extent.
This has been shown by both physical (temperature) and genetic
(coding and non-coding) manipulations of CHO cells, which either
reduce or arrest growth, facilitating enhanced speciﬁc productivity
(Barron et al., 2011a; Fogolin et al., 2004; Kaufmann et al., 2001;
Sunley and Butler, 2010; Yoon et al., 2003). Stable overexpression
of miR-17, however, slightly increases growth but at the same time
signiﬁcantly enhances productivity. This parallel induction of both
cell-speciﬁc growth rate and productivity is unique and requires a
more detailed investigation of the precise interactions and effects
caused by miR-17. So far, literature indicates that the six mature
miRNAs derived from the cluster play a role in several hematopoi-
etic malignancies, solid tumors and lung carcinoma (Olive et al.,
2010) and in B lymphomagenesis (He et al., 2005) and that these
miRNAs act as important components of the pathways that regulate
many genes involved in G1/S-phase cell cycle. This would explain
their signiﬁcant roles during tumor development and tumor main-
tenance (Yang et al., 2013). It has been shown that miR-17–92 can
target several other cellular pathways (e.g., Wnt, Jak/Stat signaling
and TGF- pathway) apart from cell cycle and apoptosis (Doebele
et al., 2010; Mestdagh et al., 2010; Uziel et al., 2009). Further, trans-
criptomic analysis of CHO clones exhibiting different growth rates
(Clarke et al., 2012) indicates a potential role of this cluster in
growth and recombinant protein production. Importantly, miR-17
was shown to target TBC1D2/Armus, which plays an important role
in membrane trafﬁcking (Serva et al., 2012) and could therefore
enhance protein secretion.
With respect to investigating miRNA function in production
relevant CHO cell lines, one needs to be aware that it is highly
dependent on cell type and the cell-speciﬁc transcriptome, respec-
tively. It is therefore not clear to what extent results obtained
with human or mouse (tumor) cell lines may be relevant for
CHO. For a more reliable prediction of miRNA function in CHO
cells, miRNA:mRNA target databases speciﬁcally designed for
CHO are urgently required. This includes thorough annotation of
mRNA untranslated regions (UTR) in the CHO genome database
(Hammond et al., 2012). For speciﬁc cases like the presented one,
the analysis of the transcriptome as well as proteome of miRNA-
engineered cell lines is required to analyze direct effects of miRs
on protein expression during each stage of the batch culture,
while methods like TAP-tar (Nonne et al., 2010) will identify direct
miRNA:mRNA interactions. Both of these approaches are currently
underway.
In conclusion, this is one of the ﬁrst reports describing stable
overexpression of miRNAs in CHO cells and analyzing its effects
on growth and recombinant protein production. Further analysis
of these stable miRNA-expressing CHO cells will provide molecular
insights eventually leading to reﬁned miRNA engineering strategies
for CHO cells.
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